Innovative and life-saving treatment options in haematology

Haematology is a focus area of high importance for medac. Related diseases affect both children and adults and are inherently life-threatening. We are committed to exploring new treatment approaches for orphan indications with limited to no treatment options.
Innovative and life-saving treatment options in haematology

Pushing the boundaries of haematological therapy

Our involvement in the field of haematology started over 20 years ago. We have focused our long-standing expertise on the development of proprietary clinical innovation, leading to the recent approval of a product used in the conditioning therapy prior to allogeneic stem cell transplantation. With this product, medac succeeded in clinically improving a substance that has been well studied in terms of its toxicity profile and tolerability. As a result it also provides access to a potentially life-saving therapy option (stem cell transplantation) for patient groups who were previously ineligible for this last potentially curative therapy option. This especially applies to elderly and co-morbid patients as well as children with malignant and non-malignant diseases.

New momentum

Prior to this new therapy standard from medac for these fragile patient groups, there had been no real progress in conditioning therapy ahead of an allogeneic stem cell transplant for years. This example illustrates how we at medac identify and address clinical needs in a targeted manner in order to improve the lives and treatment options for patients.

Expertise in haematology

Today, medac has profound expertise in haematology and a very broad portfolio around our focus products, with a reputation as an exceptionally reliable partner that offers the highest level of service. Through the years of research and development, medac has built up an extensive network of specialists, opinion leaders, and therapists, who form the foundation for further research and the expansion of therapeutic areas based on the identified clinical need. Furthermore, not only do we support clinical trials and other research to expand the use of our products in haematology, we also support education and knowledge transfer to the medical field. This is how we ensure that even more patients can benefit from our products.

Providing reliability

By manufacturing according to European quality standards, we can guarantee that our products used worldwide are of high quality and stability. The reliable supply also plays a key role in the development of new products. Our efforts to continuously optimise production processes have ultimately led to the development of products, that address patients’ as well as clinical needs in a targeted manner.

Reporting an adverse event

Apart from the desired effects, medical products can have side effects that are unpleasant or unintended. At medac, we continually collate information about side effects in order to monitor the benefit risk balance of each medication throughout its marketing lifecycle, and if necessary, can take action to better protect patient safety.

Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to medac Pharma at info@medacpharma.co.uk

We may contact you to gain further details about the report. However we are unable to provide medical advice. If you are concerned about any aspect of your treatment please discuss this with your healthcare professional (such as a doctor, nurse or pharmacist).



Please enter your email address and password to log in.